On November 18, 2021, the U.S. Department of Health and Human Services (HHS), announced the Biden administration has secured 10 million courses of the COVID-19 oral antiviral drug Paxlovid from Pfizer. Paxlovid will help to reduce hospitalizations and save lives. This drug can block an enzyme the SARS-CoV-2 virus needs to replicate in human cells. Pfizer is seeking an emergency use authorization (EUA) or approval from the U.S. Food and Drug Administration (FDA).Through this purchase agreement, the U.S government can receive 10 million treatment courses for $5.295 billion. Read more here.